Expression profiles associated with aggressive behavior in Merkel cell carcinoma

Modern Pathology

Volumn 20, Issue 1, 2007, Pages 90-101

  Fernández Figueras, María Teresa ^a   Puig, Lluís ^b   Musulén, Eva ^a   Gilaberte, Montserrat ^b   Lerma, Enrique ^b   Serrano, Sergio ^b   Ferrándiz, Carlos ^a   Ariza, Aurelio ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Carcinoma; Merkel; Neuroendocrine; Prognosis; Skin; Tissue microarray

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; SYNAPTOPHYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; VASCULOTROPIN;

AGGRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MERKEL CELL TUMOR; METASTASIS; PRIORITY JOURNAL; STAINING; STATISTICAL SIGNIFICANCE; STROMA CELL; TISSUE MICROARRAY;

CARCINOMA, MERKEL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MATRIX METALLOPROTEINASES, SECRETED; NEOPLASM INVASIVENESS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROGNOSIS; SKIN NEOPLASMS; SPAIN; SYNAPTOPHYSIN; TIME FACTORS; TISSUE ARRAY ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845690895     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800717     Document Type: Article

References (58)

1. Moll I, Zieger W, Schmelz M. Proliferative Merkel cells were not detected in human skin. Arch Dermatol Res 1996;288:184-187.
2. Allen PJ, Bowne WB, Jaques DP, et al. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol 2005;23:2300-2309.
3. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 2003;49:832-841.
4. Skelton HG, Smith KJ, Hitchcock CL, et al. Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol 1997;37:734-739.
5. Tai P, Tonita J, Yu E, et al. Twenty-year follow-up study of long-term survival of limited-stage small-cell lung cancer and overview of prognostic and treatment factors. Int J Radiat Oncol Biol Phys 2003;56:626-633.
6. Van Gele M, Boyle GM, Cook AL, et al. Gene-expression profiling reveals distinct expression patterns for classic versus variant Merkel cell phenotypes and new classifier genes to distinguish Merkel cell from small-cell lung carcinoma. Oncogene 2004;23:2732-2742.
7. Fernandez-Figueras MT, Puig L, Musulen E, et al. Prognostic significance of p27Kip1, p45Skp2 and Ki67 expression profiles in Merkel cell carcinoma, extracutaneous small cell carcinoma, and cutaneous squamous cell carcinoma. Histopathology 2005;46:614-621.
8. Llombart B, Monteagudo C, Lopez-Guerrero JA, et al. Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology 2005;46:622-634.
9. Popp S, Waltering S, Herbst C, et al. UV-B-Type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer 2002;99:352-360.
10. Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005;5:203-220.
11. Milanes-Yearsley M, Hammond EH, Pajak TF, et al. Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol 2002;15:1366-1373.
12. Rosen DG, Huang X, Deavers MT, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004;17:790-797.
13. Poulsen MG. Merkel-cell carcinoma of the skin. Lancet Oncol 2004;10:593-599.
14. Sidhu GS, Chandra P, Cassai ND. Merkel cells, normal and neoplastic: an update. Ultrastruct Pathol 2005;29:287-294.
15. Hong SM, Kim MJ, Pi DY, et al. Neuroendocrine differentiation in extrahepatic bile duct carcinomas and its prognostic significance. Hum Pathol 2005;36:732-740.
16. Howe MC, Chapman A, Kerr K, et al. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology 2005;46:195-201.
17. Pelosi G, Pasini F, Sonzogni A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I non-small cell lung carcinoma. Cancer 2003;97:2487-2497.
18. van Krimpen C, Elferink A, Broodman CA, et al. The prognostic influence of neuroendocrine differentiation in breast cancer: results of a long-term follow-up study. Breast 2004;13:329-333.
19. Kurokawa M, Nabeshima K, Akiyama Y, et al. CD56: a useful marker for diagnosing Merkel cell carcinoma. J Dermatol Sci 2003;31:219-224.
20. Koljonen V, Haglund C, Tukiainen E, et al. Neuroendocrine differentiation in primary Merkel cell carcinomapossible prognostic significance. Anticancer Res 2005;25:853-858.
21. Kennedy MM, Blessing K, King G, et al. Expression of bcl-2 and p53 in Merkel cell carcinoma. An immunohistochemical study. Am J Dermatopathol 1996;18:273-277.
22. Feinmesser M, Halpern M, Kaganovsky E, et al. c-kit expression in primary and metastatic Merkel cell carcinoma. Am J Dermatopathol 2004;26:458-462.
23. Kanazawa N, Moriyama M, Onizuka T, et al. Expression of bcl-6 protein in normal skin and epidermal neoplasms. Pathol Int 1997;47:600-607.
24. Kobielak A, Fuchs E. Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc Natl Acad Sci USA 2006;103:2322-2327.
25. Vandoros GP, Konstantinopoulos PA, Sotiropoulou-Bonikou G, et al. PPAR-gamma is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J Cancer Res Clin Oncol 2006;132:76-84.
26. Chang PY, Miyamoto S. Nuclear factor-kappaB dimer exchange promotes a p21(waf1/cip1) superinduction response in human T leukemic cells. Mol Cancer Res 2006;4:101-112.
27. Yokomizo A, Tindall DJ, Drabkin H, et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998;17:475-479.
28. Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002;8:1178-1184.
29. Van Gele M, Leonard JH, Van Roy N, et al. Frequent allelic loss at 10q23 but low incidence of PTEN mutations in Merkel cell carcinoma. Int J Cancer 2001;92:409-413.
30. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006;5:1087-1098.
31. Mosca A, Berruti A, Russo L, et al. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 2005;28:141-145.
32. Grabowski P, Griss S, Arnold CN, et al. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Neuroendocrinology 2005;81:1-9.
33. Sui L, Dong Y, Watanabe Y, et al. Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors. Oncol Rep 2006;15:773-778.
34. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev 2003;2:717-725.
35. Vicent S, Garayoa M, Lopez-Picazo JM, et al. Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 2004;10:3639-3649.
36. Tang J, Qi X, Mercola D, et al. Essential role of p38gamma in K-Ras transformation independent of phosphorylation. J Biol Chem 2005;280:23910-23917.
37. Houben R, Michel B, Vetter-Kauczok CS, et al. Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. Invest Dermatol 2006;126:1135-1142.
38. Gauthier ML, Pickering CR, Miller CJ, et al. p38 regulates cyclooxygenase-2 in human mammary epithelial cells and is activated in premalignant tissue. Cancer Res 2005;65:1792-1799.
39. Koljonen V, Lassus P, Tukiainen E, et al. Cyclooxygenase-2 expression in primary Merkel cell carcinoma. J Cutan Pathol 2005;32:55-58.
40. Dales JP, Garcia S, Meunier-Carpentier S, et al. Overexpression of hypoxia-inducible factor HIF-1 alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer 2005;116:734-739.
41. Tan C, de Noronha RG, Roecker AJ, et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 2005;65:605-612.
42. Penneys NS, Shapiro S. CD44 expression in Merkel cell carcinoma may correlate with risk of metastasis. J Cutan Pathol 1994;21:22-26.
43. Mittal K. The 9 lives of beta-catenin. Hum Pathol 2004;35:647-648.
44. Xu HT, Wang L, Lin D, et al. Abnormal beta-catenin and reduced axin expression are associated with poor differentiation and progression in non-small cell lung cancer. Am J Clin Pathol 2006;125:534-541.
45. Nitadori J, Ishii G, Tsuta K, et al. Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel. Am J Clin Pathol 2006;125:682-692.
46. Tanaka Y, Sano T, Qian ZR, et al. Expression of adhesion molecules and cytokeratin 20 in Merkel cell carcinomas. Endocr Pathol 2004;15:117-129.
47. Massi D, Franchi A, Ketabchi S, et al. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin. Hum Pathol 2003;34:80-88.
48. Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283.
49. Kren L, Goncharuk VN, Krenova Z, et al. Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms. Clinicopathologic studies. Cesk Patol 2006;42:16-19.
50. Pelosi G, Scarpa A, Veronesi G, et al. A subset of high-grade pulmonary neuroendocrine carcinomas shows up-regulation of matrix metalloproteinase-7 associated with nuclear beta-catenin immunoreactivity, independent of EGFR and HER-2 gene amplification or expression. Virch Arch 2005;447:969-977.
51. Zhang J, Jin X, Fang S, et al. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 2005;26:1748-1753.
52. Wang CS, Wu TL, Tsao KC, et al. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Ann Clin Lab Sci 2006;36:23-30.
53. Cruz-Muñoz W, Kim I, Khokha R. TIMP-3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene 2006;25:650-655.
54. Michael M, Babic B, Khokha R, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999;17:1802-1808.
55. Tunuguntla R, Ripley D, Sang QX, et al. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 2003;89:453-459.
56. Jiang X, Huang X, Li J, et al. Relationship between tissue inhibitors of metalloproteinase and metastasis and prognosis in breast cancer. Zhonghua Wai Ke Za Zhi 2000;38:291-293.
57. Dammann R, Strunnikova M, Schagdarsurengin U, et al. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer 2005;41:1223-1236.
58. Hansen TP, Nielsen O, Fenger C. Optimization of antibodies for detection of the mismatch repair proteins MLH1, MSH2, MSH6, and PMS2 using a biotin-free visualization system. Appl Immunohistochem Mol Morphol 2006;14:115-121.